Skip to main content
What types of page to search?

Popular pages: Undergraduate Postgraduate PhD Accommodation Research International students

Alternatively use our A-Z index.
Saye Khoo

Professor Saye Khoo
MB,BS, MRCP, DTM&H, FRCP, MD, Diploma in Epidemiology

Professor(Clin, Hcc)
Pharmacology & Therapeutics
Part of
Institute of Systems, Molecular & Integrative Biology
Faculty of Health and Life Sciences

Contact

S.H.Khoo@liverpool.ac.uk

Centre for Experimental Therapeutics (TherEx)

+44 (0)151 794 5560

Professional Activities

DECLARATION OF INTEREST - MY ETHOS

Individuals who offer clinical advice, or who are involved in drafting local or national guidelines and policies are rightly expected to conduct themselves in an ethical and transparent manner, without bias, and without the perception of bias. Equally, support from the Pharmaceutical Industry and Charities has yielded patient benefits which would not otherwise have accrued through exclusive reliance on the NHS or other funding agencies. Examples of this in my case are pharmaceutical support for investigator-led clinical studies, participation in educational programmes, conference attendance and sponsorship of the HIV and hepatitis drug interactions websites. In all cases these activities are strictly governed by principles established by the UK ABPI.

My personal ethos is as follows:
• I do not engage in activity which is intended to be promotional in nature, favouring one company or product above another.
• I accept speakers fees for lectures only where these are for the sole purpose of medical education or stimulating clinical debate, using slides I have personally assembled or vetted. I do not use trade names when identifying drugs, and avoid displaying corporate logos. I declare my interests at the start or end of all my talks.
• Any ‘expert’ opinions I advance are backed up by data where available, and with no influence from whoever is sponsoring the meeting.
• I accept research funding support for clinical studies only if they address an important and relevant clinical problem. These studies are led, conceived, executed and analysed by my research team.
• I also participate in international, multi-centre clinical trials of new drugs funded by industry, as long as they are clinically relevant, ethically approved and medically justified.
• While the HIV and hepatitis drugs interactions websites receive industry sponsorship, editorial content remains independent, and overseen by an International Editorial Board (see www.hiv-druginteractions.org and www.hepatitis-druginteractions.org for details). We are occasionally challenged by our users over certain drug interaction calls we have made, and while this may prompt a review, any subsequent change is only made by the editorial team using robust evaluation criteria we have established around strength of recommendation and quality of evidence (based on GRADE).
• I submit annual declarations of Interest to the Royal Liverpool University Hospital NHS Trust

Competing Interests (2022):

Research Support
• ViiV Healthcare (DolPHIN and DoRIS studies in Kampala and Cape Town)
• Merck (DORADO trial in South Africa)
• Gilead (HAART-CT study, PK of HCV drugs)
• GSK / Vir (AGILE CST-5 trial)
• Ridgeback (AGILE CST-2 trial)

Other Sponsorship
• HIV Drug Interactions tools (Gilead, ViiV, Merck, Janssen, British HIV Association, European AIDS Clinical Society, Glasgow HIV Conference)
• Hepatitis Drug Interactions tools (Gilead, AbbVie, Janssen, European Association for the Study of Liver Diseases)
• Cancer Drug Interactions tools (GIlead, Astellas, AstraZeneca, Boehringer Ingelheim, BMS, Ipsen, Janssen, Pfizer, Roche, Sanofi)
• COVID Drug Interactions tools (Novartis, Abbvie, Gilead, MSD, Sobi)

Speakers Honoraria
• ViiV, Pfizer

Conference Attendance
• nil

Advisory Boards
• ViiV, Pfizer

Patents, royalties, financial interest in pharmaceutical industry
• nil (and no family interests)

Private practice
• nil

Conference Roles

  • HIV-TB interactions, by Invitation (Karolinska Instituet, 2011)
  • Treating HIV & comorbidity: drug interactions , by Invitation (European AIDS Clincial Society, 2011)
  • Interaction between HCV and HIV drugs: present status and future development , by Invitation (Nordic HIV Physicians, 2011)
  • PK-PD Modelling & Personalised Medicine, by Invitation (Deutsch-Österreichischer AIDS-Kongress , 2011)
  • Managing Drug-Drug interactions, by Invitation (HIV Medical Association of India, 2011)
  • HIV Pharmacology, by Invitation (Advanced Course in HIV Medicine, 2011)
  • Pharmacogenetics of HIV, by Invitation (Wellcome PKPD Network, 2011)
  • TDM in guidelines and clinical practice, by Invitation (Univ of Torino, 2011)
  • Epidemiology of Drug Interactions, by Invitation (10th international congress on HIV and Drug Therapy in HIV Infection, 2010)
  • Relevance of ARV PK in the CNS, by Invitation (10th international congress on HIV and Drug Therapy in HIV Infection, 2010)
  • HIV for Generalists, by Invitation (Royal College of Physicians , 2010)
  • Drug interactions related to HIV-TB co-infected patients, by Invitation (3rd International workshop on Clinical Pharmacology of TB drugs, 2010)
  • Understanding pharmacokinetics and therapeutic drug monitoring of current antiretrovirals in childre, by Invitation (CHIVA, 2010)
  • Clinical & Pharmacological aspects of Neuropsychiatric symptoms in HIV, by Invitation (3rd International Simposium on Psychiatry & HIV, 2010)
  • Pharmacology Case Discussion (Chair), by Invitation (BHIVA, 2010)
  • PK-PD modelling in HIV, by Invitation (Wellcome Trust's Frontiers Meetings programme, 2010)
  • TDM in guidelines and clinical practice, by Invitation (University of Torino, Italy, 2010)
  • Interactions between HIV and Malaria, by Invitation (10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, 2009)
  • What TDM can and cannot tell you, by Invitation (4th Residential Course in Clinical Pharmacology of Antiretrovirals, University of Torino, Italy, 2009)
  • Pharmacology, metabolism and transport of HIV drugs into viral reservoirs, by Invitation (HIV DART 2008, Frontiers in Drug Development in Antiretroviral Therapies, Puerto Rico, 2008)
  • Drug interactions which really matter, by Invitation (9th International Congress on Drug Therapy in HIV Infection, Glasgow, 2008)
  • Pharmacology of HIV Treatment Failure, by Invitation (Dept of Infectious Diseases, Tan Tock Seng Hospital, Singapore, 2008)
  • Session Chair & Organising Committee, by Invitation (1st International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Toronto, 2008)
  • Interactions between HIV and Hepatitis C, by Invitation (2nd International Workshop on Clinical Trial Design: Experimental HCV Drugs for HIV/HCV Coinfected People, Spain, 2008)
  • What TDM can and cannot tell you, by Invitation (3rd Residential Course in Clinical Pharmacology of Antiretrovirals, Uni of Torino, Italy, 2007)
  • Pharmacogenetics and HIV Treatment, by Invitation (GSK Sponsored Meeting, London, 2007)
  • Interactions between Malaria and HIV, by Invitation (EDCTP Clinical Pharmacology Network Meeting, Kampala, 2007)
  • HIV-TB Drug Interactions, by Invitation (Inter TB Conference, St George's Hospital, 2007)
  • Therapeutic Drug Monitoring, by Invitation (Boehringer Ingelheim European Investigator's Meeting, Milan, 2007)
  • Drug Interactions, by Invitation (Human Healthcare Research Foundation / Grant Medical College, Mumbai, India, 2007)
  • Drug Interactions & Roundtable Discussion, by Invitation (Mumbai, India, 2007)
  • The pharmacology of HIV Treatment Failure, by Invitation (Institute of Virology, UCL,, 2006)
  • Choosing a nucleoside backbone, by Invitation (Serviço de Doenças Infecciosas, Hospital de Santa Maria, Lisboa, Lisbon, Portugal, 2006)
  • Drug interactions, by Invitation (Security & Simplicity, Abbot Symposium, Lake Maggiore, Italy, 2006)
  • Pharmacokinetic considerations for antiretroviral therapy, by Invitation (Gilead, 2006)
  • HIV Lipodystrophy Syndrome (Chair & Speaker), by Invitation (British Association for Sexual Health & HIV, 2006)
  • (Chair & speaker) Once-daily Treatment – What’s in a name?, by Invitation (British HIV Association, 2006)
  • Update on therapeutic drug monitoring- a critical review, by Invitation (European HIV Drug Resistance Workshop, 2006)
  • Therapeutic Drug Monitoring, by Invitation (University of Turin, 2006)
  • HIV Clinical Guidelines, by Invitation (European Congress of Chemotherapy, 2005)
  • HIV lipodystrophy, by Invitation (British Association of Sports Medicine, 2005)
  • Pros and Cons of Once-daily Regimens, by Invitation (Gilead Europe Ltd, 2005)
  • Pharmacokinetic considerations for antiretroviral therapy, by Invitation (Gilead (Europe), 2005)
  • First line regimens- a PK perspective, by Invitation (National AIDS Manual, 2005)
  • Therapeutic Drug Monitoring, by Invitation (British Association of Sexual Health & HIV, 2005)
  • Drug Interactions, by Invitation (University of Turin. , 2005)

Editorships

  • HIV Treatment Bulletin (Editorial Consultant, 2004 - present)
  • Journal of Antimicrobial Chemotherapy (Editor, 2003 - present)

Examination Roles

  • University of Leiden (Holland), PhD (2013)
  • Imperial College, University of London, UK, PhD (2011)
  • University of Cape Town South Africa, PhD (2011)
  • Karolinska Institute, PhD (2011)
  • Karolinska Institute, University of Stockholm, PhD (2010)

Organisations I have been associated with

  • www,hep-druginteractions.org
  • Sahir House ( Mersey HIV Community Group)
  • www.hiv-druginteractions.org

Professional Body Memberships

  • British Infection Society (Member)
  • British HIV Association (Member)
  • World Health Organisation (Committee Member, 2010 - present)
  • World Health Organisation (WHO Expert Advisory, 2004 - 2005)
  • Royal College of Physicians (Fellow, 2004 - present)
  • World Health Organisation (WHO Expert Advisory, 2004 - 2005)
  • British Society for Antimicrobial Chemotherapy (Member, 2003 - present)